NCT04605120 is a NA clinical trial of Cervical fusion in Cervical Fusion, sponsored by Biobank.

Who is sponsoring NCT04605120?

NCT04605120 is sponsored by Biobank.

What drugs are being tested in NCT04605120?

Interventions in NCT04605120: Cervical fusion.

What condition does NCT04605120 study?

NCT04605120 studies Cervical Fusion, Cervical Disc Degeneration, Spinal Fusion.

Is NCT04605120 still recruiting?

NCT04605120 is currently status unknown. Last updated 27 October 2020.

Last reviewed 2020-10-27 · How we verify

NCT04605120

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allogeinic Bone Paste

Status unknown NA Last updated 27 October 2020

What this trial tests

NA trial testing Cervical fusion in Cervical Fusion in 50 participants. Status unknown.

Timeline

15 September 2020

Primary endpoint
30 June 2023

30 September 2023

Quick facts

Lead sponsor	Biobank
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	15 September 2020
Primary completion	30 June 2023
Estimated completion	30 September 2023
Sites	1 location across France

Drugs / interventions tested

Cervical fusion

Conditions studied

Cervical Fusion — all drugs for Cervical Fusion →
Cervical Disc Degeneration — all drugs for Cervical Disc Degeneration →
Spinal Fusion — all drugs for Spinal Fusion →

Sponsor

Biobank — full company profile →

Who can join

18 and older, any sex, with Cervical Fusion or Cervical Disc Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single arm, single center clinical study to evaluate efficacy and safety of a Supercritical CO2 viral-inactivated allogenic bone paste in cervical interbody fusion. Patient eligible for 1- or 2-level ACDF (Anterior Cervical Discectomy and Fusion) combined with bone graft after failure of well-conducted medical treatment will be screened for the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Precision medicine strategies for spinal degenerative diseases: Injectable biomaterials with in situ repair and regeneration.
Zhao X, Ma H, Han H, Zhang L, et al · · 2022 · cited 22× · PMID 35799898 · DOI 10.1016/j.mtbio.2022.100336

Verify or expand the search:

Other recruiting trials for Cervical Fusion

Currently open trials in the same condition.

NCT04623593 — Cervical Arthroplasty Cost Effectiveness Study (CACES) · NA · recruiting
NCT04640896 — Trigger Point Injections in Anterior Cervical Surgery · Phase 4 · recruiting

Other Biobank trials

Trials by the same sponsor.

NCT04141215 — Allogeneic Bone Paste Versus Allogeneic Bone Powder · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04605120 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biobank
Last refreshed: 27 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04605120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing